At the 20th Congress of the European Hematology Association (EHA), Barbara Eichhorst, MD, of the University of Cologne, Cologne, Germany, summarises clinical trials being conducted by the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) in patients with chronic lymphocytic leukemia (CLL), including a chemotherapy-free treatment with obinutuzumab plus chlorambucil; a watch-and-wait strategy; and a four-arm study comparing standard chemotherapy versus non-chemotherapy-containing regimens.